
Personalisation of therapy for people with type 2 diabetes and cardiovascular disease risk
Feb 14, 2024 - 00:11:56
Radio and PodcastLive Radio & Podcasts
The SURPASS program of phase 3 clinical trials led to the 2022 FDA approval and positive CHMP opinion of the first GIP/GLP-1 receptor agonist, tirzepatide. Join Prof Carol Wysham for an examination of the clinical data f...
Publication special: Data from the SURPASS program With Prof Carol Wysham is an episode from Diabetes Knowledge into Practice Podcast by Liberum IME. The SURPASS program of phase 3 clinical trials led to the 2022 FDA approval and positive C...
This episode belongs to Diabetes Knowledge into Practice Podcast.
Use the player on this page to stream the episode online.
Published Sep 27, 2022, 00:13:35 long, audio available.